FRM
RCUS icon

Fox Run Management’s Arcus Biosciences RCUS Stock Holding History

Fox Run Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,985
Closed -$133K – 1161
2025
Q1 		$133K Buy
+16,985
New +$197K 0.02% 843
2024
Q1 		– Sell
-15,418
Closed -$294K – 1013
2023
Q4 		$294K Sell
15,418
-4,408
-22% -$70.5K 0.08% 500
2023
Q3 		$356K Buy
+19,826
New +$398K 0.11% 378

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Fox Run Management's RCUS Position: Q2 2025 in Review

Fox Run Management sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 16,985 shares — an estimated $133K sold.

Fox Run Management first reported a position in RCUS in Q3 2023 and held it in 3 quarters. The position peaked at $356K in Q3 2023. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Fox Run Management reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 16,985 Arcus Biosciences shares in Q2 2025, an estimated $133K.
  • Fox Run Management first reported a position in Arcus Biosciences in Q3 2023 and held it in 3 quarters.
  • Fox Run Management's Arcus Biosciences position peaked at $356K in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.